Cargando…

Current and Future Neuropharmacological Options for the Treatment of Essential Tremor

BACKGROUND: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropatholog...

Descripción completa

Detalles Bibliográficos
Autores principales: Alonso-Navarro, Hortensia, García-Martín, Elena, Agúndez, José A.G., Jiménez-Jiménez, Félix J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457404/
https://www.ncbi.nlm.nih.gov/pubmed/31976837
http://dx.doi.org/10.2174/1570159X18666200124145743
_version_ 1783575987234013184
author Alonso-Navarro, Hortensia
García-Martín, Elena
Agúndez, José A.G.
Jiménez-Jiménez, Félix J.
author_facet Alonso-Navarro, Hortensia
García-Martín, Elena
Agúndez, José A.G.
Jiménez-Jiménez, Félix J.
author_sort Alonso-Navarro, Hortensia
collection PubMed
description BACKGROUND: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. METHODS: A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. RESULTS: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. CONCLUSION: Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABA(A) receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future.
format Online
Article
Text
id pubmed-7457404
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-74574042020-12-01 Current and Future Neuropharmacological Options for the Treatment of Essential Tremor Alonso-Navarro, Hortensia García-Martín, Elena Agúndez, José A.G. Jiménez-Jiménez, Félix J. Curr Neuropharmacol Article BACKGROUND: Essential Tremor (ET) is likely the most frequent movement disorder. In this review, we have summarized the current pharmacological options for the treatment of this disorder and discussed several future options derived from drugs tested in experimental models of ET or from neuropathological data. METHODS: A literature search was performed on the pharmacology of essential tremors using PubMed Database from 1966 to July 31, 2019. RESULTS: To date, the beta-blocker propranolol and the antiepileptic drug primidone are the drugs that have shown higher efficacy in the treatment of ET. Other drugs tested in ET patients have shown different degrees of efficacy or have not been useful. CONCLUSION: Injections of botulinum toxin A could be useful in the treatment of some patients with ET refractory to pharmacotherapy. According to recent neurochemical data, drugs acting on the extrasynaptic GABA(A) receptors, the glutamatergic system or LINGO-1 could be interesting therapeutic options in the future. Bentham Science Publishers 2020-06 2020-06 /pmc/articles/PMC7457404/ /pubmed/31976837 http://dx.doi.org/10.2174/1570159X18666200124145743 Text en © 2020 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Alonso-Navarro, Hortensia
García-Martín, Elena
Agúndez, José A.G.
Jiménez-Jiménez, Félix J.
Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
title Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
title_full Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
title_fullStr Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
title_full_unstemmed Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
title_short Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
title_sort current and future neuropharmacological options for the treatment of essential tremor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457404/
https://www.ncbi.nlm.nih.gov/pubmed/31976837
http://dx.doi.org/10.2174/1570159X18666200124145743
work_keys_str_mv AT alonsonavarrohortensia currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor
AT garciamartinelena currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor
AT agundezjoseag currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor
AT jimenezjimenezfelixj currentandfutureneuropharmacologicaloptionsforthetreatmentofessentialtremor